Economic evaluation of hematopoietic growth factor using French DRG data;Utilisation du PMSI pour l'evaluation economique des facteurs de croissance hematopoietiques

Journal d'Economie Medicale

Volumn 16, Issue 4-5, 1998, Pages 265-274

  Livartowski, A ^a   Gastaldi, C ^a   Kletz, F ^b   Spira, R ^b   Palangie T ^a   Launois, R ^c   Moisdon, J C ^b   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

^b MINES ParisTech   (France)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

Breast Cancer; Chemotherapy; Cost effectiveness analysis; Hematopoietic growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

APHERESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; ECONOMIC EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; SEPSIS;

EID: 0032408176     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Osborne CK. Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat 1991;20:S11-S14.
2. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer : Yes. In : Important advances in oncology 1995. Philadelphia : Lippincott Company. 1995: 215-230.
3. Le Corroller AG, Moatti JP, Detournay B, Fagnani F, Biaise D, Maraninchi D. L'évaluation des facteurs de croissance hématopoïétiques (FCH) : de la minimisation des coûts à une véritable analyse économique. Cah Oncol 1993;2:267-273.
4. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5.
5. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose R et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematotherapy 1992;1:317-327.
6. Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant : neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12:661-670.
7. Legros M, Fleury J, Curé H. Rhu GMCSF after high dose chemotherapy and peripheral blood stem cell rescue : an unicenter randomized study of 50 patients. SFGM. Abstract 1994.
8. Sheridan WP, Begley CG, Juttner CA, Szer J, Bik To L, Maher D et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. The Lancet 1992;339:640-644.
9. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C et al. Comparative effects of granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating Factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;817:1709-1719.
10. Kucharski AJ, Ghalie R, Greenstein S, Matuszewki K. The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cell as rescue therapy following autologous bone marrow transplant. International Journal of Technology Assessment in Health Care 1996;72;1: 172-179.
11. Le Corroller AG, Moatti JP, Detournay B, Fagnani F, Biaise D et al. L'évaluation économique du G-CSF en thérapeutique cancérologique : deux études françaises. La Presse Médicale 1994;23;24:1105-1109.
12. Weber RJ. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Clinical Therapeutics 1993;75; 1:180-191.
13. Le PMSI. Analyse médico-économique de l'activité hospitalière. Ministère du Travail et des Affaires Sociales. La lettre d'Informations hospitalières - Numéro spécial - mai 1996.
14. Echelle Nationale de Coûts Relatifs par Groupe Homogène de Malade 1995. Bulletin Officiel. Fascicule spécial no 95-5 bis.